Neuraxis Inc Stock Price, News & Analysis

NeurAxis (NYSE American: NRXS) reported third quarter 2025 results and operational milestones on November 11, 2025. Revenues rose 22% year-over-year to $811,000 and unit deliveries increased ~38% year-over-year. Gross margin declined to 83.3% from 85.4% due to higher discounting and expired inventory. Operating expenses were $2.8M and operating loss was $2.1M, wider than a year earlier. Cash was $4.4M at September 30, 2025, with an additional $2.8M raised in October 2025 via an ATM offering and warrant exercises.

Key operational wins include multiple FDA clearances (expanded IB-Stim indications to ages 8–21, allowance of 4 devices per patient, FD indication with nausea, and 510(k) for RED), a new CPT Category I code effective January 1, 2026, and expanded covered lives to ~55 million.

NeurAxis (NYSE: NRXS) will release its third quarter 2025 financial results for the period ended September 30, 2025, on Tuesday, November 11, 2025 before market open.

The company will host a conference call and live webcast the same day at 9:00 a.m. Eastern Time. Webcast access and a replay will be available in the Investor Relations section at https://ir.neuraxis.com/ and at the provided media-server link. Participants may submit questions via the webcast portal or by emailing NRXS@lythampartners.com.

NeurAxis (NYSE:NRXS) received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) device to treat functional abdominal pain associated with functional dyspepsia (FD) and FD-related nausea in patients aged 8 years and older on October 24, 2025. The FDA reviewed randomized trials and real-world evidence, extrapolating pediatric data to adults. This is described as the first FDA clearance for a treatment addressing adult functional dyspepsia. NeurAxis noted the new indication will use the Category I CPT code effective January 1, 2026 to report PENFS procedures.

NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025.

The company will deliver a virtual webcast presentation at 11:00 a.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be available for replay after the event through the conference website.

NeurAxis (NYSE American: NRXS) reported strong Q2 2025 financial results, with revenues increasing 46% year-over-year to $894,000. The medical technology company, focused on neuromodulation therapies, achieved significant milestones including FDA clearance for expanded pediatric treatment and secured key academic society guidelines recommendation for their PENFS technology.

Operating expenses decreased 10% year-over-year, while operating loss improved by 22%. The company maintained a cash balance of $6 million, bolstered by a $5 million equity financing round. NeurAxis expanded its covered lives to 53 million and received a new Category I CPT code for PENFS procedures, effective January 2026. The company expects to achieve breakeven in 2026.

NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions, has scheduled its Q2 2025 earnings call for Tuesday, August 12, 2025, at 9:00 AM ET. The financial results will be released before the market opens.

The company will host a live webcast accessible through their investor relations website, with options for participants to submit questions through the webcast portal or via email. A replay of the webcast will be available on the company's website following the call.

NeurAxis (NYSE: NRXS) has secured medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology from two health insurers, adding 700,000 covered lives in Connecticut and Massachusetts. This brings their total national coverage to approximately 53 million members. The company's FDA-cleared IB-Stim device treats functional abdominal pain associated with IBS and Pediatric Functional Dyspepsia in patients aged 8-21 years through non-surgical electrical stimulation of cranial nerves. The technology has been included in pediatric academic society's treatment guidelines, and a Category I CPT code will become effective January 1, 2026, which is expected to improve reimbursement and adoption across children's hospitals.

NeurAxis (NRXS) has achieved a significant milestone as its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been included in new clinical practice guidelines for treating Functional Abdominal Pain in IBS. The guidelines, published in the Journal of Pediatric Gastroenterology & Nutrition, recommend PENFS as one of only four highest-evidence therapies. NeurAxis's IB-Stim is the only FDA-cleared treatment recommended in the guidelines for pediatrics, targeting patients aged 8-21. This recognition is expected to facilitate widespread insurance coverage and market adoption. The company estimates a $3 billion addressable market in the US alone, with over 600,000 affected children. The guidelines were developed collaboratively by European and North American pediatric gastroenterology societies using the WHO-supported GRADE approach.

NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.

The company will deliver a webcast presentation at 9:30 a.m. ET and conduct one-on-one meetings with investors throughout the event. Interested parties can access the webcast through the conference website or directly via the provided link, with replay options available after the event.